SPYRE THERAPEUTICS INC(SYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SYRE SPYRE THERAPEUTICS INC

已收盘 07-21 16:00:00 EDT

102.70

+5.37

+5.52%

盘后102.70

+0.000.00%

19:57 EDT

最高103.31	最低98.50	成交量77.65万
今开99.07	昨收97.33	日振幅4.94%
总市值89.19亿	流通市值83.16亿	总股本8,684万
成交额7,891万	换手率0.96%	流通股本8,098万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SYRE","market":"US","secType":"STK","nameCN":"SPYRE THERAPEUTICS INC","latestPrice":102.7,"timestamp":1784664000000,"preClose":97.33,"halted":0,"volume":776543,"hourTrading":{"tag":"盘后","latestPrice":102.7,"preClose":102.7,"latestTime":"19:57 EDT","volume":22648,"amount":2325900.265,"timestamp":1784678258988,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.055173122367204404,"floatShares":80977000,"shares":86841253,"eps":-2.12,"marketStatus":"已收盘","change":5.37,"latestTime":"07-21 16:00:00 EDT","open":99.07,"high":103.31,"low":98.5,"amount":78910412.66051,"amplitude":0.04942,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.12,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1784707200000},"marketStatusCode":5,"adr":0,"listingDate":1460001600000,"exchange":"NASDAQ","adjPreClose":97.33,"preHourTrading":{"tag":"盘前","latestPrice":99.29,"preClose":97.33,"latestTime":"09:28 EDT","volume":17,"amount":1697.90509,"timestamp":1784640499026,"change":1.96,"changeRate":0.020138,"amplitude":0.024607},"postHourTrading":{"tag":"盘后","latestPrice":102.7,"preClose":102.7,"latestTime":"19:57 EDT","volume":22648,"amount":2325900.265,"timestamp":1784678258988,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.517052,"impliedVol":0.8603,"impliedVolPercentile":0.753},"requestUrl":"/m/hq/s/SYRE","defaultTab":"news","newsList":[{"id":"1177727349","title":"异动解读｜Spyre Therapeutics盘中上涨11.41%，报104.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177727349","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177727349?lang=zh_cn&edition=full","pubTime":"2026-07-15 00:01","pubTimestamp":1784044892,"startTime":"0","endTime":"0","summary":"7月15日，Spyre Therapeutics盘中上涨11.41%，报104.42美元/股，成交额7429.81万美元。Spyre Therapeutics所在的生物科技行业中，个股表现分化，其中Nextcure Inc.涨213.3%，渤健公司跌8.42%，艾伯维公司跌1.24%，Shuttle Pharmaceuticals Inc涨31.42%，吉利德科学跌0.49%。Spyre Therapeutics是一家临床阶段生物技术公司，致力于通过结合同类最佳的抗体工程、合理的治疗组合以及精准医疗方法，开发下一代炎症性肠病产品，管线涵盖针对α4β7、TL1A和IL-23的延长半衰期抗体。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193512223","title":"异动解读｜Spyre Therapeutics盘中上涨5.02%，报93.505美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193512223","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193512223?lang=zh_cn&edition=full","pubTime":"2026-07-08 00:15","pubTimestamp":1783440956,"startTime":"0","endTime":"0","summary":"7月8日，Spyre Therapeutics盘中上涨5.02%，报93.505美元/股，成交额3902.22万美元。Spyre Therapeutics所在的生物科技行业中，个股中，福泰制药跌1.11%，艾伯维公司涨0.99%，吉利德科学涨3.70%，Moderna跌3.34%，安进涨0.46%。Spyre Therapeutics是一家临床阶段生物技术公司，旨在通过结合同类最佳的抗体工程、合理的治疗组合以及精准医疗方法，创造下一代炎症性肠病产品，产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121929272","title":"异动解读｜SPYRE THERAPEUTICS盘前下跌5.04%，董事减持持续施压股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1121929272","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121929272?lang=zh_cn&edition=full","pubTime":"2026-06-25 16:18","pubTimestamp":1782375497,"startTime":"0","endTime":"0","summary":"6月25日，SPYRE THERAPEUTICS盘前下跌5.04%，报82.44美元/股，成交额1.8万美元。消息面上，公司董事Michael Thomas Henderson于6月22日出售2万股公司股票，总价值约200万美元，该消息于6月23日披露后持续发酵。此前交易日公司股价已大幅下挫逾13%，成交量超290万股，约为日均成交量的两倍以上。Spyre Therapeutics是一家专注于炎症性肠病的生物技术公司，产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143725534","title":"异动解读｜Spyre Therapeutics盘中下跌14.76%，董事减持引发市场关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1143725534","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143725534?lang=zh_cn&edition=full","pubTime":"2026-06-24 21:38","pubTimestamp":1782308280,"startTime":"0","endTime":"0","summary":"6月24日，Spyre Therapeutics盘中下跌14.76%，报85.19美元/股，成交额3673.81万美元。消息面上，公司于6月23日披露内部交易情况，董事HENDERSON MICHAEL THOMAS于6月22日卖出2万股公司股票。对于一家尚处于亏损阶段、市盈率为负的临床期生物技术公司而言，高管减持信号容易放大市场对公司前景的疑虑。Spyre Therapeutics是一家专注于炎症性肠病的生物技术公司，产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体，当前市净率约12.39倍，总市值约83亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134617087","title":"异动解读｜SPYRE THERAPEUTICS盘前下跌10.83%，报86.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134617087","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134617087?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:02","pubTimestamp":1782288144,"startTime":"0","endTime":"0","summary":"6月24日，SPYRE THERAPEUTICS盘前下跌10.83%，报86.54美元/股，成交额1.75万美元。SPYRE THERAPEUTICS所在的生物科技行业中，个股表现分化，艾伯维公司涨0.63%，Apogee Therapeutics涨1.44%，吉利德科学跌0.14%，安进跌0.42%，再生元制药公司涨0%。其产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133633236","title":"异动解读｜SPYRE THERAPEUTICS夜盘下跌7.91%，报89.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133633236","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133633236?lang=zh_cn&edition=full","pubTime":"2026-06-24 08:23","pubTimestamp":1782260607,"startTime":"0","endTime":"0","summary":"6月24日，SPYRE THERAPEUTICS夜盘下跌7.91%，报89.37美元/股，成交额179.0美元。SPYRE THERAPEUTICS所在的生物科技行业中，个股表现平淡，艾伯维公司涨0%，Apogee Therapeutics涨0%，吉利德科学跌0.94%，安进涨0%，再生元制药公司涨0%。其产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121301590","title":"异动解读｜SPYRE THERAPEUTICS盘后上涨8.19%，报105.0美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1121301590","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121301590?lang=zh_cn&edition=full","pubTime":"2026-06-24 04:41","pubTimestamp":1782247295,"startTime":"0","endTime":"0","summary":"6月23日，SPYRE THERAPEUTICS盘后上涨8.19%，报105.0美元/股，成交额411.19万美元。SPYRE THERAPEUTICS所在的生物科技行业中，个股表现分化，艾伯维公司跌0.22%，Apogee Therapeutics跌0.14%，吉利德科学涨0.32%，再生元制药公司跌0.01%，安进跌0.58%。其产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132100150","title":"Spyre Therapeutics：二十名受试者出现治疗引发不良事件；两例严重，均与药物无关","url":"https://stock-news.laohu8.com/highlight/detail?id=1132100150","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132100150?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:03","pubTimestamp":1781525007,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics公布了一项临床试验的更新数据，显示有二十名受试者出现了治疗引发的不良事件。其中，两例被评估为严重级别，但经过分析，这些严重事件均被判定与试验药物本身无关。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107639416","title":"SPYRE THERAPEUTICS：Spy002在第12周实现33%临床缓解与42%内镜改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1107639416","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107639416?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:02","pubTimestamp":1781524958,"startTime":"0","endTime":"0","summary":"SPYRE THERAPEUTICS公司宣布，其候选药物Spy002在治疗第12周时取得了令人鼓舞的临床数据。\n结果显示，接受治疗的患者中有33%达到了临床缓解的标准。同时，内镜检查评估显示，42%的患者实现了内镜下病情的显著改善。\n这些中期数据为该药物的后续开发提供了积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178318875","title":"Spyre公布其潜在同类最佳药物Spy002（抗TL1A）在Skyline试验中治疗中重度溃疡性结肠炎患者的A部分诱导结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1178318875","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178318875?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:01","pubTimestamp":1781524915,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics公司宣布，其候选药物Spy002（一种抗TL1A疗法）在针对中重度溃疡性结肠炎患者的Skyline试验中，取得了A部分的诱导期结果。数据显示，该药物展现出成为同类最佳疗法的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196395365","title":"Spyre Therapeutics宣布Skyway篮子试验完成患者入组，评估Spy072（抗TL1A）治疗RA、PsA及AxSpa","url":"https://stock-news.laohu8.com/highlight/detail?id=1196395365","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196395365?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:08","pubTimestamp":1780488531,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc (SPYRE THERAPEUTICS INC) 已宣布，其针对Spy072（一种抗TL1A疗法）的Skyway篮子试验患者入组工作现已完成。该试验旨在评估该疗法对类风湿关节炎（RA）、银屑病关节炎（PsA）以及中轴型脊柱关节炎（AxSpa）患者的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146674317","title":"Spyre Therapeutics重申预期：类风湿关节炎试验数据将于2026年第三季度揭晓，银屑病关节炎与中轴型脊柱关节炎数据预计第四季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1146674317","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146674317?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:06","pubTimestamp":1780488378,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics公司再次确认其关键临床试验的预期数据公布时间线。针对类风湿关节炎（Ra）的研究数据，预计将在2026年第三季度获得并公布。此外，关于银屑病关节炎（Psa）以及中轴型脊柱关节炎（Axspa）的试验数据，公司则预计将在2026年第四季度陆续揭晓。\n这一时间表的重申，为关注该公司研发管线的投资者提供了明确的关键节点。不同适应症的数据分阶段出炉，或将影响市场对公司未来前景的评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162858091","title":"Spyre Therapeutics：Skyway与Skyline试验齐头并进，计划中的“2026年六项”二期数据读出已就绪并按计划推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1162858091","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162858091?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:06","pubTimestamp":1780488377,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics宣布，其Skyway与Skyline临床试验项目进展顺利，原定于2026年完成的六项二期研究数据读出已具备条件，并正按既定时间表稳步推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179769071","title":"Spyre Therapeutics重大协议触发条款：2028年6月1日后初始领域外给药限制将解除","url":"https://stock-news.laohu8.com/highlight/detail?id=1179769071","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179769071?lang=zh_cn&edition=full","pubTime":"2026-06-02 04:06","pubTimestamp":1780344382,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）的一份文件披露，Spyre Therapeutics Inc.已达成一项重大协议。该协议包含一项关键条款：自2028年6月1日起，针对初始领域之外的给药限制将被解除。这一变动标志着公司研发管线在特定时间点后将获得更广泛的开发自由度，可能为后续临床试验的拓展铺平道路。文件显示，此次协议触发的限制解除是预先设定的条件之一，符合公司长远的战略规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150438791","title":"Spyre Therapeutics 与 Paragon Therapeutics 签署许可协议首次修订案","url":"https://stock-news.laohu8.com/highlight/detail?id=1150438791","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150438791?lang=zh_cn&edition=full","pubTime":"2026-06-02 04:05","pubTimestamp":1780344311,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc (股票代码: SYRE) 于2026年5月29日，与Paragon Therapeutics就其许可协议签署了第一份修订案。该信息已通过美国证券交易委员会（SEC）文件正式披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138781160","title":"Spyre Therapeutics公布2026年一季度财务数据：现金及等价物达7.415亿美元 资金可支撑运营至2029年下半年","url":"https://stock-news.laohu8.com/highlight/detail?id=1138781160","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138781160?lang=zh_cn&edition=full","pubTime":"2026-05-05 20:11","pubTimestamp":1777983099,"startTime":"0","endTime":"0","summary":"生物制药公司Spyre Therapeutics Inc最新财务数据显示，截至2026年3月31日，公司持有的现金、现金等价物及有价证券总额达到7.415亿美元。这一资金规模预计能为公司持续运营提供充足保障，资金跑道将延续至2029年下半年。\n值得注意的是，强劲的现金储备为Spyre Therapeutics推进其创新疗法研发提供了坚实后盾。在当前生物科技领域融资环境充满挑战的背景下，该公司依然保持着稳健的财务态势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120556014","title":"异动解读 | Spyre Therapeutics获强力买入评级，盘前大涨6.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1120556014","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120556014?lang=zh_cn&edition=full","pubTime":"2026-04-14 21:31","pubTimestamp":1776173485,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc（SYRE）今日盘前股价大涨6.99%，引起了市场的关注。消息面上，Raymond James分析师马丁・奥斯特首次覆盖Spyre Therapeutics，并给予其“强力买入”评级，目标价设定为80美元。该目标价显著高于公司股票周一63.27美元的收盘价，这向市场传递了积极的信号，增强了投资者对公司未来股价表现的信心，从而推动了股价在盘前交易中上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627469264","title":"【券商聚焦】华尔街顶尖分析师调整闪迪等多家企业评级展望","url":"https://stock-news.laohu8.com/highlight/detail?id=2627469264","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627469264?lang=zh_cn&edition=full","pubTime":"2026-04-14 20:12","pubTimestamp":1776168740,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华尔街头部分析师近期陆续更新多家热门上市公司的投资评级与目标价：Evercore ISI分析师阿米特达里亚尼首次覆盖闪迪 ，给予其跑赢大盘评级，设定目标价 1200 美元。摩根士丹利分析师罗纳德坎德姆首次覆盖Janus Living，给出增持评级，目标价定为 28 美元。Evercore ISI 分析师彼得莱文首次覆盖边缘云服务商Fastly，评级为跑赢大盘，目标价 32 美元，该股周一收盘价 24.37 美元。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/ZWQyMzQ4MWViNTBlNjYyZWIyNzg3MGMyMTYyODU5MDY5NTc1OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZWQyMzQ4MWViNTBlNjYyZWIyNzg3MGMyMTYyODU5MDY5NTc1OQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299168","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4170","BK4225","BK4608","BK4554","SNXX","BK4120","LU0054578231.USD","FSLY","SYRE","BK4613","LU0963586101.USD","BK4585","JAN","SNDK","BK4139","BK4116","BK4007","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104189294","title":"Spyre Therapeutics公司宣布暂停并终止ATM发行招股说明书 2026年4月13日正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1104189294","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104189294?lang=zh_cn&edition=full","pubTime":"2026-04-14 04:31","pubTimestamp":1776112280,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会的文件显示，生物制药公司Spyre Therapeutics Inc已决定暂停并终止其在场内发行计划相关的招股说明书。该决定将于2026年4月13日正式生效。这意味着Spyre Therapeutics公司将不再通过ATM发行方式出售普通股。ATM发行是一种灵活的融资方式，允许上市公司在需要时通过经纪商在公开市场上逐步出售股票。暂停和终止ATM招股说明书的举措，通常意味着公司短期内不会通过该渠道进行股权融资。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627458246","title":"Spyre盘前股价上涨23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627458246","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627458246?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:47","pubTimestamp":1776080820,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月13日，Spyre盘前股价上涨23%。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-04-13/doc-inhukeex9689769.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-04-13/doc-inhukeex9689769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SYRE","LU2250418816.HKD","BK4543","LU1852331112.SGD","BK4585","BK4528","IE00B19Z9P08.USD","LU1861215975.USD","BK4023","BK4613","LU0353189680.USD","LU0353189763.USD","LU2087625088.SGD","IE00B19Z9Z06.USD","LU2290526834.HKD","BK4588","LU1861220033.SGD","LU2360107168.USD","LU0056508442.USD","AIYY","BK4551","BK4539","BK4608","IE00B894F039.SGD","LU2063271972.USD","APPX","LU2360106780.USD","IE00BZ9MQY76.HKD","BK4587","LU0097036916.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.spyre.com","stockEarnings":[{"period":"1week","weight":0.0384},{"period":"1month","weight":0.1018},{"period":"3month","weight":0.3657},{"period":"6month","weight":1.8635},{"period":"1year","weight":4.9748},{"period":"ytd","weight":1.971}],"compareEarnings":[{"period":"1week","weight":-0.0095},{"period":"1month","weight":-0.0062},{"period":"3month","weight":0.054},{"period":"6month","weight":0.0827},{"period":"1year","weight":0.1825},{"period":"ytd","weight":0.0882}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Spyre Therapeutics, Inc.于2013年12月16日从特拉华州有限责任公司转换而来。该公司是一家生物技术公司，旨在通过结合同类最佳的抗体工程、合理的治疗组合以及用于患者选择的精准医疗方法，创造下一代炎症性肠病（IBD）产品。Spyre的产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.035303},{"month":2,"riseRate":0.5,"avgChangeRate":0.028912},{"month":3,"riseRate":0.5,"avgChangeRate":0.022238},{"month":4,"riseRate":0.2,"avgChangeRate":-0.009955},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.054533},{"month":6,"riseRate":0.454545,"avgChangeRate":0.127238},{"month":7,"riseRate":0.454545,"avgChangeRate":0.006729},{"month":8,"riseRate":0.8,"avgChangeRate":0.108946},{"month":9,"riseRate":0.6,"avgChangeRate":0.016514},{"month":10,"riseRate":0.4,"avgChangeRate":0.109394},{"month":11,"riseRate":0.4,"avgChangeRate":0.005048},{"month":12,"riseRate":0.4,"avgChangeRate":-0.019416}],"exchange":"NASDAQ","name":"SPYRE THERAPEUTICS INC","nameEN":"SPYRE THERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SPYRE THERAPEUTICS INC(SYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供SPYRE THERAPEUTICS INC(SYRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"SPYRE THERAPEUTICS INC,SYRE,SPYRE THERAPEUTICS INC股票,SPYRE THERAPEUTICS INC股票老虎,SPYRE THERAPEUTICS INC股票老虎国际,SPYRE THERAPEUTICS INC行情,SPYRE THERAPEUTICS INC股票行情,SPYRE THERAPEUTICS INC股价,SPYRE THERAPEUTICS INC股市,SPYRE THERAPEUTICS INC股票价格,SPYRE THERAPEUTICS INC股票交易,SPYRE THERAPEUTICS INC股票购买,SPYRE THERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SPYRE THERAPEUTICS INC(SYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供SPYRE THERAPEUTICS INC(SYRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}